Crizotinib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 197-205

  Heigener, David F ^a   Reck, Martin ^a  

^a Department of Thoracic Oncology LungenClinic Grosshansdorf ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; KETOCONAZOLE; MIDAZOLAM; REACTIVE OXYGEN METABOLITE; RIFAMPICIN; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EWING SARCOMA; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LARGE CELL LYMPHOMA; LIVER LEVEL; LUNG CANCER; NAUSEA; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; PERIPHERAL EDEMA; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; STOMACH CARCINOMA; VISUAL DISORDER; VOMITING; ANIMAL; DRUG EFFECT; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 84906927012     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_11     Document Type: Article

References (29)

1. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011-1019
2. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734-1739
3. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12):3314-3322
4. Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D et al (2013) Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leuk Res 37(5):520-530
5. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29(15):e443-e445
6. Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymalepithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54(18):6342-6363
7. Curran MP (2012) Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72(1):99-107
8. Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW et al (2013) Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int J Cancer 133(2):427-436
9. Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R et al (2013) Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 8(3):373-384
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693-1703
11. Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY et al (2013) Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119(9):1627-1635
12. Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18(10):2740-2753
13. Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H et al (2012) Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 11(7):1557-1564
14. Ordemann R, Stohlmacher J, Beuthien-Baumann B, Platzek I, van den Hoff J, Kroschinsky F et al (2013) Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 92(1):125-127
15. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW et al (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6(5):942-946
16. Ou SH, Bang YJ, Camidge DR, Riely G (2013) Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cll lung cancer (NSCLC). J Clin Oncol 31:8032
17. Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH et al (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77(2):288-292
18. Rodig SJ, Shapiro GI (2010) Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Invest Drugs 11(12):1477-1490
19. Salgia R, Solomon B, Shaw AT, Camidge DR (2011) Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib. J Clin Oncol 30:7596
20. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L et al (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70(24):10038-10043
21. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004-1012
22. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ et al (2013a) Crizotinib versus Chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394
23. Shaw AT, Mehra R, Kim DW, Felip E (2013b) Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 31(suppl), abstr 8010. 2013
24. Takeda M, Okamoto I, Nakagawa K (2013) Clinical impact of continued Crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8(5):654-657
25. Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H et al (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in nonsmall cell lung cancer according to MET alterations. J Thorac Oncol 6(10):1624-1631
26. Tothova Z, Wagner AJ (2012) Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol 24(4):409-413
27. Xalkori (crizotinib) prescribing information. Pfizer Inc. 2012
28. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB (2012) Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1- translocated lung cancer. J Thorac Oncol 7(7):1086-1090
29. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67(9):4408-4417